Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Agent using hsp47 inhibitor to suppress metastasis

A cancer metastasis and substance technology, applied in medical preparations, drug combinations, biochemical equipment and methods containing active ingredients, etc., can solve the problem that there is no treatment method, breast cancer treatment methods are not effective, and there is no effective cancer cell metastasis. treatment, etc.

Pending Publication Date: 2021-04-30
NITTO DENKO CORP
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Triple-negative breast cancer is negative for expression of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) and has high metastatic ability, so the existing breast cancer treatment methods ( Chemotherapy, hormone therapy, molecular targeted therapy) have little effect, and the status quo is that there is no solution for it
However, effective treatments for inhibiting cancer cell metastasis in general have not been established
Thus, for breast cancer, especially triple-negative breast cancer, the mechanism of acquiring high metastatic ability has not yet been elucidated, and there is no therapeutic method capable of controlling / suppressing metastasis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent using hsp47 inhibitor to suppress metastasis
  • Agent using hsp47 inhibitor to suppress metastasis
  • Agent using hsp47 inhibitor to suppress metastasis

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0097] Example 1: Acquisition and cultivation of cell lines

[0098] All human breast cancer cell lines (MDA-MB-468, MDA-MB-231, MDA-MB-157, MCF7, BT474) used in the specification of this application were purchased from American Type Culture Collection. These cells were cultured in Dulbecco's modified Eagle medium (DMEM, Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS, Invitrogen Life Technologies).

example 2

[0099] Example 2: HSP47 in human breast cancer cells Expression of mRNA and HSP47 protein

[0100] Detection of 3 types of triple-negative human breast cancer cells (MDA-MB-468, MDA-MB-231, MDA-MB-157) and 2 types of non-triple-negative human breast cancer cells (MCF7, BT474) by real-time PCR and Western Blotting Expression of HSP47 mRNA and HSP47 protein in . show the result in figure 1 .

[0101] The mRNA expression in the 3 triple negative human breast cancer cells was significantly lower compared to the mRNA expression in the 2 non-triple negative human breast cancer cells. Likewise, the expression of HSP47 protein in 3 types of triple-negative human breast cancer cells was also significantly lower than that in 2 types of non-triple-negative human breast cancer cells.

example 3

[0102] Example 3: HSP47-positive cell rate in triple-negative human breast cancer cells

[0103] Two kinds of triple-negative human breast cancer cells (MDA-MB-231, MDA-MB-157) were mixed with 1×10 6 The concentration of cells / 50 μL PBS was subcutaneously transplanted into Balb / c nu / nu mice. After tumor formation, tumor cells were harvested and analyzed by flow cytometry using an anti-HSP47 antibody (Enzo Life Sciences). show the result in figure 2 . 19.7% of MDA-MB-231 cells expressed HSP47, and 16.7% of MDA-MB-157 cells expressed HSP47.

[0104] Therefore, if figure 1 As shown, the expression of HSP47 in cell-cultured triple-negative breast cancer was weakly positive. However, if figure 2 As shown, when triple-negative breast cancer cells were placed in an in vivo environment, the expression of HSP47 was high.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a metastasis suppressing agent containing a HSP47 inhibitor.

Description

technical field [0001] The present invention relates to medicines and methods for inhibiting cancer metastasis. Background technique [0002] In cancer therapy, therapy based on induction of cancer cell death, therapy based on inhibition of proliferation of cancer cells, and therapy based on removal of cancer tissue are mainstream, but therapy based on the inhibition of metastasis of cancer cells in combination with these treatments has a negative impact on preventing cancer progression, cancer The recurrence point of view is important. However, effective treatments for inhibiting cancer cell metastasis have not yet been achieved. Therefore, in cancer therapy, it is desired to establish a method for suppressing metastasis of cancer cells. As a cancer treatment method, Patent Document 1 describes treating tumors by inhibiting tumor growth using molecules targeting heat shock protein 47 (HSP47). [0003] Triple-negative breast cancer is negative for expression of estrogen r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/7088A61K31/7105A61K31/713A61P35/04A61P43/00
CPCA61K31/713A61P35/04C12N15/113C12N2310/14C12N2310/531A61K31/7105A61K45/06C12N15/1135C12N2310/11C12N2310/12C12N2310/141
Inventor 米田明弘田村保明武井则雄泽田香织
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com